RxDoctor Payments DataLook up a doctor →

Christopher Laganke, MD

Neurology · Cullman, ALNPI 1811931546

Payments from drug & device makers

$5,868,493in general payments, 2019–2025

Across 2,759 payments — averaging $2127.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.1M
  • Genentech, Inc.$1.1M
  • Sanofi$1M
  • Biogen$687K
  • EMD Serono, Inc.$282K
  • TG Therapeutics, Inc.$255K
  • plus $473K from 54 others
$12,199in research payments, 2019–2025

Across 38 payments — averaging $321.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$12K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis205$2,050,132
Genentech, Inc.91$1,100,479
Sanofi235$1,019,989
Biogen290$687,384
EMD Serono, Inc.275$282,441
TG Therapeutics, Inc.151$254,806
Alkermes, Inc.32$99,464
Bristol Myers Squibb107$83,279
Adamas Pharmaceuticals, Inc.41$70,695
Sanofi-aventis U.S. LLC11$42,971
Ares Trading SA16$41,559
Genentech USA, Inc.105$32,058
E.r. Squibb & Sons, L.L.C.17$19,054
AbbVie(2 entities)153$18,952
Sanofi US Services Inc.2$12,675
Mallinckrodt Hospital Products Inc.47$11,750
Johnson & Johnson55$8,693
AstraZeneca20$7,652
Mallinckrodt Enterprises LLC9$7,626
UCB, Inc.286$2,899
Biohaven Pharmaceutical Holding Company Ltd.14$2,495
Biohaven Pharmaceuticals, Inc.14$1,856
Amgen(2 entities)69$1,627
Acorda Therapeutics, Inc34$600
Eisai Inc.31$599
Argenx US, Inc.30$584
Lilly USA, LLC26$406
Neurelis, Inc.18$397
Corium, LLC84$379
Axsome Therapeutics, Inc.25$331
Teva Pharmaceuticals USA, Inc.29$320
CSL Behring11$305
Takeda Pharmaceuticals U.S.A., Inc.19$289
Neurocrine Biosciences, Inc.8$201
Banner Life Sciences, LLC10$192
Ipsen Biopharmaceuticals, Inc10$192
Scilex Pharmaceuticals Inc.12$186
MDD US Operations, LLC10$178
Supernus Pharmaceuticals, Inc.10$173
Grifols USA, LLC8$169
Arbor Pharmaceuticals, Inc.11$158
Upsher-smith Laboratories LLC11$149
Collegium Pharmaceutical, Inc.10$146
Avanir Pharmaceuticals, Inc.9$146
Cycle Pharmaceuticals Inc6$146
Catalyst Pharmaceuticals, Inc.7$141
Pfizer8$135
SK Life Science, Inc.6$124
Jazz Pharmaceuticals Inc.6$121
Harmony Biosciences LLC5$112
Octapharma USA, Inc.5$104
Kyowa Kirin, Inc.6$96
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$87
Merz Pharmaceuticals, LLC3$75
Axonics, Inc.1$72
Vanda Pharmaceuticals Inc.3$67
Acadia Pharmaceuticals Inc4$65
Boston Scientific4$60
Neos Therapeutics, LP4$57
Sunovion Pharmaceuticals Inc.3$44

How this compares

$5,868,493 in reported general payments places this provider in the 95th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$7,082,590
Medicare patients
554
Services billed
217,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →